Related Experiment Videos
Combination insulin-sulfonylurea therapy
1Department of Medicine, State University of New York Health Science Center, Brooklyn 11203.
Abstract:
Combination sulfonylurea-insulin therapy for patients with diabetes mellitus has been evaluated by numerous investigators with various experimental designs. Much of the data are conflicting, and clear conclusions do not seem justified. Insulin-sulfonylurea therapy is probably not clinically useful in most patients with insulin-dependent diabetes mellitus. Most non-insulin-dependent diabetic (NIDDM) patients are also unlikely to have meaningful improvement in glycemic regulation on insulin-sulfonylurea therapy. A subset of NIDDM patients who are mildly to moderately obese, have adequate endogenous insulin secretory reserve, and are in poor glycemic regulation (fasting plasma glucose greater than 11 mM and/or HbA1 greater than 10%), despite twice-daily insulin administration of greater than 70 U/day, may show significant improvement of glycemic regulation and/or decreases in insulin daily dose on insulin-sulfonylurea therapy. The mechanisms by which insulin-sulfonylurea therapy improves glycemic regulation and decreases insulin requirements involve an increase in endogenous insulin secretion and possibly some extrapancreatic actions of the sulfonylureas on muscle and liver.
Insights
Combination sulfonylurea-insulin therapy offers limited benefits for most diabetes mellitus patients. However, a specific subset of obese non-insulin-dependent diabetes mellitus patients may see improved glycemic control and reduced insulin needs.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Combination therapy of sulfonylureas and insulin for diabetes mellitus has been investigated using diverse methodologies.
- Existing data present conflicting results, hindering definitive conclusions regarding its efficacy.
Purpose of the Study:
- To evaluate the clinical utility and effectiveness of combined sulfonylurea-insulin therapy in managing diabetes mellitus.
- To identify patient subgroups that may benefit from this combination treatment.
Main Methods:
- Review and synthesis of existing research on insulin-sulfonylurea combination therapy.
- Analysis of patient characteristics, glycemic control metrics, and insulin dosage in response to the therapy.
Main Results:
- Insulin-sulfonylurea therapy is generally not clinically beneficial for most patients with insulin-dependent diabetes mellitus.
- Most non-insulin-dependent diabetes mellitus (NIDDM) patients show minimal improvement with this combination.
- A specific NIDDM subset (mild-moderate obesity, adequate insulin reserve, poor glycemic control despite high insulin doses) may experience significant glycemic improvement and reduced insulin requirements.
Conclusions:
- The combination of sulfonylureas and insulin is unlikely to be beneficial for the majority of diabetes mellitus patients.
- Potential benefits are restricted to a select group of NIDDM patients, suggesting a need for personalized treatment approaches.
- Mechanisms for improvement in the identified subset include enhanced endogenous insulin secretion and potential extrapancreatic effects of sulfonylureas.